Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21208926 | 0.89 | TSHR (0.43) | LRRK2SMN1; SMN2JAK2JAK3NPC1 | |
| SCHEMBL21216920 | 0.83 | PRKDC (0.52) | KDM4EGAAMAPTLRRK2HTT | |
| SCHEMBL21209380 | 0.82 | KDM4E (0.47) | KDM4EGAAMAPTRXFP1NPC1 | |
| SCHEMBL21209778 | 0.81 | KDM4E (0.47) | KDM4EGAAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL21210752 | 0.79 | CYP1A2 (0.52) | KDM4EGAAMAPTSMN1; SMN2CYP2C19 | |
| SCHEMBL21210940 | 0.76 | HTT (0.47) | LRRK2HTTSMN1; SMN2CYP2C19JAK2 | |
| SCHEMBL21208256 | 0.71 | SMN1; SMN2 (0.53) | KDM4EGAAMAPTHTTSMN1; SMN2 | |
| SCHEMBL21209364 | 0.70 | DRD1 (0.41) | KDM4EGAAMAPTLRRK2 | |
| SCHEMBL21209372 | 0.69 | CSNK1E (0.49) | — | |
| SCHEMBL10272311 | 0.69 | CYP2C19 (0.63) | GAAMAPTLRRK2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KDM4E 3944/4885GAA 133/4885MAPT 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.